FINNENCE ▪ THE WIRE FILE
THE WIRE · № 78055
Company■ Unclear/unknown
New Phase 3 trial: Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia — Il-Yang Pharm. Co., Ltd.
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Combination BPH therapy trial; incremental in a generic-heavy space.
Combination BPH therapy enters Phase 3
CATALYST TO WATCH
Trial results timing
MAIN RISK
Generic competition limits upside
FULL DISPATCH
Sponsor: Il-Yang Pharm. Co., Ltd.; Status: Not Yet Recruiting; Conditions: Benign Prostatic Hyperplasia; Interventions: Finasteride 5 mg Tablet, single dose, Tamsulosin 0.4Mg Capsule; Enrollment: 660 (estimated); First posted: 2026-10-13; NCT: NCT07870759
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Phase 3 trial: To Evaluate HU-045 With Moderate to Severe Glabellar Lines — Huons Biopharma2026-10-13 12:00 UTC
New Phase 3 trial: To Evaluate HU-045 With Moderate to Severe Glabellar Lines — Huons Biopharma2026-10-13 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight — Amgen2026-10-13 12:00 UTC
New Phase 3 trial: Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight — Amgen2026-10-13 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.